{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:57Z","timestamp":1793656677168,"version":"4.5.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca Gothenburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jchf.2024.12.012","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T14:53:58Z","timestamp":1741791238000},"page":"102393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F.","family":"Docherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0366-5492","authenticated-orcid":false,"given":"David D.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-3359","authenticated-orcid":false,"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hammarstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Sj\u00f6strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.12.012_bib1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2024.12.012_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.12.012_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.12.012_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","article-title":"HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation","volume":"30","author":"Petrie","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2024.12.012_bib5","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2024.12.012_bib6","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.12.012_bib7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.12.012_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010051","article-title":"Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction","volume":"16","author":"Mooney","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.12.012_bib9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.12.012_bib10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.12.012_bib11","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2337\/dc22-0866","article-title":"Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS","volume":"45","author":"Koshino","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2024.12.012_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/1744666X.2022.2045952","article-title":"Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives","volume":"18","author":"Kreiner","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jchf.2024.12.012_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN110223","article-title":"Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy","volume":"97","author":"Sanchez-Alamo","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jchf.2024.12.012_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jchf.2024.12.012_bib15","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.12.012_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114224","article-title":"Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms","volume":"296","author":"Lau","year":"2021","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jchf.2024.12.012_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jchf.2021.09.002","article-title":"Effect of dapagliflozin, compared with placebo, according to baseline risk in DAPA-HF","volume":"10","author":"Docherty","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.12.012_bib18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ejhf.1482","article-title":"The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study","volume":"21","author":"Markousis-Mavrogenis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.12.012_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","article-title":"Interleukin-6 in patients with heart failure and preserved ejection fraction","volume":"11","author":"Alogna","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.12.012_bib20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.109.849117","article-title":"Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA)","volume":"120","author":"McMurray","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.12.012_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131818","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: findings from TOPCAT","author":"Ferreira","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2024.12.012_bib22","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jchf.2024.12.012_bib23","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of Interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.12.012_bib24","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1111\/bcp.14725","article-title":"Inhibition of interleukin 6 signalling and renal function: a Mendelian randomization study","volume":"87","author":"Ryan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jchf.2024.12.012_bib25","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.12.012_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.12.012_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jchf.2024.12.012_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","article-title":"Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats","volume":"56","author":"Mel\u00e9ndez","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2024.12.012_bib29","article-title":"Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGF\u03b21 and miR-29 pathways","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2024.12.012_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jchf.2024.12.012_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-022-01463-2","article-title":"The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)","volume":"21","author":"Omar","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2024.12.012_bib32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamacardio.2019.5850","article-title":"Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish heart failure registry to predict mortality and morbidity in chronic heart failure","volume":"5","author":"Simpson","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:15:44Z","timestamp":1758989744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213177925000903"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.12.012","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102393"}}